601607 上海医药
已收盘 08-21 15:00:00
资讯
新帖
简况
上海医药：公司进口总代业务多年处于全国领先地位
证券之星 · 08-21 18:16
上海医药：公司进口总代业务多年处于全国领先地位
上海医药：公司益生菌产品已搭建起覆盖多元消费场景的完善大健康产品矩阵
证券之星 · 08-20 17:27
上海医药：公司益生菌产品已搭建起覆盖多元消费场景的完善大健康产品矩阵
胡庆余堂药业年产22亿粒胶囊剂生产车间建设项目开工
第一财经 · 08-18
胡庆余堂药业年产22亿粒胶囊剂生产车间建设项目开工
上海医药：自2025年起已启动应收账款专项管理工作
证券之星 · 08-12
上海医药：自2025年起已启动应收账款专项管理工作
股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》
证券之星 · 08-05
股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》
股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》
证券之星 · 08-04
股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》
上海医药最新公告：奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产
证券之星 · 08-03
上海医药最新公告：奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产
每周股票复盘：上海医药（601607）瑞舒伐他汀依折麦布片获准生产
证券之星 · 08-02
每周股票复盘：上海医药（601607）瑞舒伐他汀依折麦布片获准生产
上海医药“存贷双高”：账上躺着327亿 短期借款仍高达440亿
中国经营网 · 08-01
上海医药“存贷双高”：账上躺着327亿 短期借款仍高达440亿
上海医药(601607.SH)：瑞舒伐他汀依折麦布片(Ⅰ)获得批准生产
智通财经 · 07-30
上海医药(601607.SH)：瑞舒伐他汀依折麦布片(Ⅰ)获得批准生产
上海医药(601607.SH)：龙虎清凉油经典款等三款产品获加拿大产品许可证
智通财经 · 07-30
上海医药(601607.SH)：龙虎清凉油经典款等三款产品获加拿大产品许可证
股市必读：上海医药（601607）7月29日董秘有最新回复
证券之星 · 07-30
股市必读：上海医药（601607）7月29日董秘有最新回复
上海医药：2026年第一季度公司药品CSO业务新承接7个品种的商业化合作
证券日报 · 07-29
上海医药：2026年第一季度公司药品CSO业务新承接7个品种的商业化合作
上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源
证券日报 · 07-29
上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源
上海医药、君实生物等成立新私募基金 出资额15亿
南方财经网 · 07-28
上海医药、君实生物等成立新私募基金 出资额15亿
上海医药2025年三大业务板块毛利率集体下滑遭问询 公司回复
南方财经网 · 07-27
上海医药2025年三大业务板块毛利率集体下滑遭问询 公司回复
出资3亿，上海医药做LP了
PE星球 · 07-26
出资3亿，上海医药做LP了
每周股票复盘：上海医药（601607）终止丹酚酸A临床试验
证券之星 · 07-26
每周股票复盘：上海医药（601607）终止丹酚酸A临床试验
上海医药（601607）披露参与设立上海上实生物医药产业私募基金暨关联交易进展，7月24日股价下跌1.27%
证券之星 · 07-24
上海医药（601607）披露参与设立上海上实生物医药产业私募基金暨关联交易进展，7月24日股价下跌1.27%
上海医药(02607)：决定终止注射用丹酚酸A的临床试验及后续开发
智通财经 · 07-24
上海医药(02607)：决定终止注射用丹酚酸A的临床试验及后续开发
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.19,"timestamp":1787295601000,"preClose":16.66,"halted":0,"volume":19485836,"delay":0,"changeRate":-0.0282,"floatShares":2789000000,"shares":3708000000,"eps":1.5666,"marketStatus":"已收盘","change":-0.47,"latestTime":"08-21 15:00:00","open":16.52,"high":16.6,"low":16.1,"amount":317000000,"amplitude":0.03,"askPrice":16.2,"askSize":99,"bidPrice":16.19,"bidSize":177,"shortable":0,"etf":0,"ttmEps":1.5666,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":16.66,"symbolType":"stock","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":18.33,"lowLimit":14.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.78,"roa":"--","peRate":10.334482,"roe":"1.85%","epsLYR":1.54,"committee":0.71701,"marketValue":60038000000,"turnoverRate":0.007,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-24。","hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.67,"timestamp":1787299688008,"preClose":11.67,"halted":0,"volume":926100,"delay":0,"premium":"-38.21"},"floatMarketCap":45157000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2661264382","title":"上海医药：公司进口总代业务多年处于全国领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264382","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661264382?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:16","pubTimestamp":1787307366,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药08月21日在投资者关系平台上答复投资者关心的问题。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0209","BK1197","BK0012","02607","BK0097","BK0183","BK0175","BK0188","BK0099","BK0028","BK0184","BK0187","601607","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400182","title":"上海医药：公司益生菌产品已搭建起覆盖多元消费场景的完善大健康产品矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400182?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:27","pubTimestamp":1787218029,"startTime":"0","endTime":"0","summary":"公司在益生菌赛道已取得积极的研发成果和市场应用，我们关心的是，现下在此方面是否还有进一步拓展？公司的益生菌产品已经搭建起覆盖多元消费场景的完善大健康产品矩阵。未来，公司将依托研发与供应链优势，持续深耕益生菌赛道，打造更具竞争力的国产益生菌品牌，为大众健康生活贡献更多力量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000030745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0012","BK0175","BK0188","BK0187","BK1197","601607","BK0183","BK0209","BK0184","BK0097","02607","BK0028","BK0099","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660445844","title":"胡庆余堂药业年产22亿粒胶囊剂生产车间建设项目开工","url":"https://stock-news.laohu8.com/highlight/detail?id=2660445844","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660445844?lang=zh_cn&edition=full","pubTime":"2026-08-18 08:19","pubTimestamp":1787012345,"startTime":"0","endTime":"0","summary":"【胡庆余堂药业年产22亿粒胶囊剂生产车间建设项目开工】据上海医药消息，8月15日上午，上海医药旗下杭州胡庆余堂药业有限公司年产22亿粒胶囊剂生产车间建设项目开工。据介绍，本次年产22亿粒胶囊剂智能车间项目是突破产能瓶颈、落地公司大品种战略的关键举措。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183843874673.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183843874673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","BK0012","BK0097","BK0187","BK0099","BK0196","BK0028","BK0183","601607","BK0184","BK0175","BK0209","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658922400","title":"上海医药：自2025年起已启动应收账款专项管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658922400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658922400?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:33","pubTimestamp":1786520031,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药08月12日在投资者关系平台上答复投资者关心的问题。公司始终高度重视现金流安全、应收账款管理与资产负债结构优化，坚持审慎稳健的财务管控原则，保障公司持续健康运营。在应收账款管理方面，自2025年起，公司已启动应收账款专项管理工作，在工业端实行“一司一策”、在商业端实行“一院一策”，结合不同区域制定差异化管控策略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200021104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","BK0175","02607","BK0012","BK0097","BK0209","BK0188","BK0184","BK1197","BK0187","BK0028","BK0196","BK0020","BK0099","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565215","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565215","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565215?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:08","pubTimestamp":1785870494,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上药信谊药厂奥美拉唑碳酸氢钠干混悬剂获国家药监局批准生产，已投入研发费用约593.55万元，2025年该药品中国大陆医院采购金额为1,569万元。公司公告汇总上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂获得批准生产的公告上海医药下属上海上药信谊药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，奥美拉唑碳酸氢钠干混悬剂获批生产。该药品用于活动性十二指肠溃疡和胃食管反流病的短期治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0012","BK0097","BK0183","02607","BK0187","BK0175","BK0020","BK1197","BK0028","BK0196","BK0184","BK0188","BK0099","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539305","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539305","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539305?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:29","pubTimestamp":1785778149,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上药信谊药厂奥美拉唑碳酸氢钠干混悬剂获国家药监局批准生产，已投入研发费用约593.55万元，2025年该药品中国大陆医院采购金额为1,569万元。公司公告汇总上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂获得批准生产的公告上海医药集团股份有限公司下属上海上药信谊药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，奥美拉唑碳酸氢钠干混悬剂获得批准生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0020","BK0099","BK0183","BK0012","BK0187","BK0184","BK0196","02607","BK0188","BK0175","BK0209","601607","BK0028","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656132424","title":"上海医药最新公告：奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2656132424","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656132424?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:50","pubTimestamp":1785747032,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属上药信谊收到国家药监局颁发的关于奥美拉唑碳酸氢钠干混悬剂(I)的《药品注册证书》，该药品获得批准生产。该药品主要用于活动性十二指肠溃疡的短期治疗和胃食管反流病。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300021820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","601607","BK0188","BK0196","BK0097","BK0209","BK0175","02607","BK0099","BK0184","BK1197","BK0183","BK0020","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656319656","title":"每周股票复盘：上海医药（601607）瑞舒伐他汀依折麦布片获准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2656319656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656319656?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:15","pubTimestamp":1785611713,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，上海医药报收于16.86元，较上周的16.38元上涨2.93%。本周，上海医药7月31日盘中最高价报16.86元。公司公告汇总上海医药集团股份有限公司下属常州制药厂有限公司收到国家药监局颁发的瑞舒伐他汀依折麦布片（Ⅰ）《药品注册证书》，该药品获得批准生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","601607","BK0097","BK0175","BK0028","BK0099","02607","BK0012","BK0020","BK0209","BK0188","BK1197","BK0187","BK0183","BK0184"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391506","title":"上海医药“存贷双高”：账上躺着327亿 短期借款仍高达440亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391506","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656391506?lang=zh_cn&edition=full","pubTime":"2026-08-01 04:28","pubTimestamp":1785529707,"startTime":"0","endTime":"0","summary":"“存贷双高的问题算是监管正式提出了。”近日，上海医药（601607.SH、2607.HK）披露2025年年报信息监管问询函回复，有投资者在平台上如此说道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608013828791364.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608013828791364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","BK0028","BK0097","BK0196","02607","BK1197","601607","BK0099","BK0175","BK0183","BK0184","BK0187","BK0188","BK0209","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782971","title":"上海医药(601607.SH)：瑞舒伐他汀依折麦布片(Ⅰ)获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782971","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655782971?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:59","pubTimestamp":1785398348,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)收到国家药品监督管理局颁发的关于瑞舒伐他汀依折麦布片(Ⅰ)的《药品注册证书》(证书编号：2026S02581)，该药品获得批准生产。瑞舒伐他汀依折麦布片适用于高胆固醇血症或纯合子型家族性高胆固醇血症(HoFH)，由Sanofi-aventis,S.R.O.公司开发，2014年07月在欧盟上市，商品名为Zenon Neo。2024年12月，常州制药厂有限公司就该药品向国家药监局提出注册上市申请，并获受理。截至公告日，公司针对该药品已投入研发费用约人民币968万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","601607","BK0188","BK0196","BK0097","BK0209","BK0175","02607","BK0099","BK0184","BK1197","BK0183","BK0020","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882925","title":"上海医药(601607.SH)：龙虎清凉油经典款等三款产品获加拿大产品许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655882925?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:57","pubTimestamp":1785398232,"startTime":"0","endTime":"0","summary":"龙虎清凉油经典款、龙虎清凉油强效款、龙虎滚珠风油精这三款产品主要适用于暂时缓解肌肉和关节的酸痛/不适。2026年5月，上药中华向加拿大卫生部天然与非处方健康产品管理局递交产品注册申请。截至本公告日，公司针对前述产品在加拿大上市已投入注册费用约人民币4.95万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","BK0097","BK0099","BK0188","BK0012","BK0184","BK0020","BK1197","BK0175","BK0187","BK0209","BK0196","BK0028","02607","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655890582","title":"股市必读：上海医药（601607）7月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655890582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655890582?lang=zh_cn&edition=full","pubTime":"2026-07-30 01:35","pubTimestamp":1785346511,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，上海医药报收于16.6元，上涨0.91%，换手率0.45%，成交量12.57万手，成交额2.09亿元。董秘最新回复投资者： 尊敬的董秘，您好！2026年《财富》世界500强企业最新发布，公司是否位列排行之中？2025年公司营业收入2,835.80亿元人民币，同比增长3.03%；实现归属于上市公司股东的净利润57.25亿元人民币，同比上升25.74%。当日关注点交易信息汇总：7月29日上海医药主力资金净流入363.7万元，游资资金净流出1609.35万元，散户资金净流入1245.65万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000000862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0097","02607","BK0184","BK0175","BK0020","BK0209","BK0099","601607","BK1197","BK0012","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655611860","title":"上海医药：2026年第一季度公司药品CSO业务新承接7个品种的商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655611860","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655611860?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:00","pubTimestamp":1785326400,"startTime":"0","endTime":"0","summary":"证券日报网7月29日讯，上海医药在接受调研时表示，2026年第一季度，公司药品CSO业务，新承接7个品种的商业化合作，产品矩阵持续优化丰富，为后续业绩增长奠定了扎实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825276947.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825276947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","BK0020","BK0099","BK1197","BK0012","BK0183","BK0196","BK0184","BK0187","BK0188","BK0097","02607","BK0209","BK0028","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860648","title":"上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860648","media":"证券日报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655860648?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:58","pubTimestamp":1785326280,"startTime":"0","endTime":"0","summary":"证券日报网7月29日讯，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825275880.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825275880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","601607","BK0188","BK0196","BK0097","BK0209","BK0175","02607","BK0099","BK0184","BK1197","BK0183","BK0020","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654020804","title":"上海医药、君实生物等成立新私募基金 出资额15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2654020804","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654020804?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:18","pubTimestamp":1785208680,"startTime":"0","endTime":"0","summary":"【上海医药、君实生物等成立新私募基金 出资额15亿】天眼查App显示，近日，上海上实生物医药产业私募基金合伙企业（有限合伙）成立，执行事务合伙人为上海上实资本管理有限公司、上海上实生物医药管理咨询有限公司，出资额15亿人民币，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由上海国投先导生物医药私募投资基金合伙企业（有限合伙）、上海医药集团股份有限公司、上海君实生物医药科技股份有限公司等共同出资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823297587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823297587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK1197","BK0020","BK0028","BK0099","BK1161","BK0012","BK0183","02607","BK0187","BK1583","BK0196","BK1515","BK0188","601607","BK0209","BK0097","BK0184","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654176095","title":"上海医药2025年三大业务板块毛利率集体下滑遭问询 公司回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654176095","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654176095?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:13","pubTimestamp":1785118380,"startTime":"0","endTime":"0","summary":"南方财经7月27日电，上交所近日就上海医药(601607.SH)2025年年报下发监管问询函，重点关注公司主营业务三大板块毛利率集体下滑。问询函要求公司补充披露工业、分销、零售板块的产品结构、集采影响及同行业对比情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273821800044.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273821800044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0028","BK0183","02607","BK0097","BK0099","BK0188","601607","BK0175","BK0187","BK0209","BK0184","BK0020","BK0196","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654068582","title":"出资3亿，上海医药做LP了","url":"https://stock-news.laohu8.com/highlight/detail?id=2654068582","media":"PE星球","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654068582?lang=zh_cn&edition=full","pubTime":"2026-07-26 08:33","pubTimestamp":1785025980,"startTime":"0","endTime":"0","summary":"截至2026年7月25日，上海医药A股总市值为607.43亿元；港股总市值为437.59亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU4MzMxMjMzOQ==&mid=2247547796&idx=2&sn=290a53102392055a5f9e65a3d04d04bc&chksm=fcaf9f7a6a9a78430aab9b558d3aba35dc67bab4606253ce35017e25cb4660966d5d971b0e3e&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0209","BK0097","BK0183","BK0020","BK0175","BK0196","601607","BK0099","BK0187","BK0184","BK0012","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052272","title":"每周股票复盘：上海医药（601607）终止丹酚酸A临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052272?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:50","pubTimestamp":1785001823,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，上海医药报收于16.38元，较上周的16.61元下跌1.38%。本周，上海医药7月21日盘中最高价报17.05元。截至公告日，项目累计投入研发费用约800万元人民币。上海医药集团股份有限公司决定终止注射用丹酚酸A的临床试验及后续开发。该项目为中药第1类创新药，拟用于冠心病心绞痛，2016年6月获准开展临床试验，现处II期阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0099","BK0209","BK0175","BK0183","BK0184","BK0187","BK0196","BK0012","BK0188","BK0097","BK0020","BK1197","BK0028","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653136038","title":"上海医药（601607）披露参与设立上海上实生物医药产业私募基金暨关联交易进展，7月24日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653136038","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653136038?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:16","pubTimestamp":1784902598,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，上海医药报收于16.38元，较前一交易日下跌1.27%，最新总市值为607.43亿元。该股当日开盘16.62元，最高16.69元，最低16.34元，成交额达1.47亿元，换手率为0.32%。近日，上海医药集团股份有限公司发布《关于参与设立上海上实生物医药产业私募基金暨关联/连交易的进展公告》。2026年7月24日，公司已签署《上海上实生物医药产业私募基金合伙企业有限合伙协议》。本次交易构成关联交易。除上述进展外，其他内容与2026年7月18日公告一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0099","BK0012","BK0184","BK0028","BK0097","BK1197","BK0020","BK0196","399441","02607","BK0183","BK0188","BK0187","601607","BK0209","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081246","title":"上海医药(02607)：决定终止注射用丹酚酸A的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653081246?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:44","pubTimestamp":1784893480,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，为合理配置研发资源、聚焦优势研发项目，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止注射用丹酚酸A的临床试验及后续开发。注射用丹酚酸A是中药1.2类创新药，拟用于冠心病心绞痛。2016年6月，该项目获国家药品监督管理局批准开展临床试验，现处于临床试验II期阶段。截至目前，该项目累计研发投入共计约人民币3743万元。为合理配置研发资源、聚焦优势研发项目，公司基于对该研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止该研发项目的临床试验及后续开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","601607","BK0175","BMED","BK0020","BK0097","BK0099","BK0188","PSYK","BK0209","BK0196","IBBQ","BK0184","BK0187","BK1197","BK0028","BK0183","IBBJ","02607","MDTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787330252077,"stockEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0334},{"period":"3month","weight":0.0055},{"period":"6month","weight":-0.0367},{"period":"1year","weight":-0.1332},{"period":"ytd","weight":-0.0682}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.0356},{"period":"ytd","weight":-0.016}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100447人(较上一季度增加Infinity%)","perCapita":"27767股","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}